| Patents for A61P 41 - Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution (3,707) |
|---|
| 11/29/2001 | WO2001090070A2 Caspase inhibitors and uses thereof |
| 11/29/2001 | WO2001089593A1 Transfection system |
| 11/29/2001 | WO2001089514A2 Pharmaceutical composition comprising a free-radical scavenging sedative agent and a metal ion chelating agent |
| 11/29/2001 | US20010047008 Allosteric adenosine receptor modulators |
| 11/29/2001 | CA2408033A1 Pharmaceutical composition comprising a free-radical scavenging sedative agent and a metal ion chelating agent |
| 11/29/2001 | CA2380935A1 Caspase inhibitors and uses thereof |
| 11/22/2001 | WO2001088103A2 Compositions and methods for tissue dedifferentiation and regeneration |
| 11/22/2001 | WO2001087870A1 Hydroxamic acid derivatives |
| 11/22/2001 | WO2001036462A3 Protein c derivatives |
| 11/22/2001 | DE10023484A1 New 2-((cycloalkyl- or heterocyclyl-alkyl)-amino)-benzamide derivatives, are VEGF receptor, KDR kinase and FLT kinase inhibitors useful e.g. for treating tumors, psoriasis, arthritis or renal or ophthalmological diseases |
| 11/22/2001 | DE10018221A1 Treating disorders of the teeth, gums or jawbones using growth hormones, preferably human growth hormone or dehydroepiandrosterone, useful e.g. for treating paradontosis or healing jaw operation wounds |
| 11/22/2001 | CA2409035A1 Hydroxamic acid derivatives |
| 11/22/2001 | CA2408701A1 Compositions and methods for tissue dedifferentiation and regeneration |
| 11/15/2001 | WO2001085719A1 Ortho-substituted anthranilic acid amides and their use as medicaments |
| 11/15/2001 | WO2001085671A2 Anthranyl amides and their use as medicaments |
| 11/15/2001 | WO2001085256A2 Critical illness neuropathy |
| 11/15/2001 | WO2001085199A1 PHARMACEUTICAL COMPOSITION COMPRISING A FACTOR VIIa AND A TFPI INHIBITOR |
| 11/15/2001 | WO2001085198A1 tHARMACEUTICAL COMPOSITION COMPRISING A FACTOR VIIA AND A FACTOR XIII |
| 11/15/2001 | WO2001085193A2 Method for promoting neovascularization using a tweak agonist and an angiogenic factor |
| 11/15/2001 | WO2001085179A2 Biological joint lubricant composition and method of applying |
| 11/15/2001 | US20010041186 Composition and method for acceleration of wound and burn healing |
| 11/15/2001 | CA2408228A1 Method for promoting neovascularization |
| 11/15/2001 | CA2407852A1 Ortho-substituted anthranilic acid amides and their use as medicaments |
| 11/15/2001 | CA2407817A1 Anthranilamides and their use as pharmaceutical agents |
| 11/14/2001 | EP1153611A2 Pharmaceutical composition for the treatment of fibrosis |
| 11/08/2001 | WO2001083522A2 Growth factor modified protein matrices for tissue engineering |
| 11/08/2001 | WO2001030383A3 Medicament in order to induce tolerance |
| 11/08/2001 | US20010038860 As active ingredient a hydrophilic polymer mainly composed of monomeric units of alkylene glycols and/or vinyl monomeric units having a nondissociating hydrophilic group |
| 11/08/2001 | US20010038840 Method for the treatment of fibrosis |
| 11/01/2001 | WO2001036604A3 Nucleic acids encoding endotheliases, endotheliases and uses thereof |
| 11/01/2001 | US20010036456 Administering Protein C |
| 10/31/2001 | EP1149116A1 Process for the production of multiple cross-linked hyaluronic acid derivatives |
| 10/31/2001 | EP1149111A1 Method and composition for angiogenesis inhibition |
| 10/31/2001 | EP1148886A2 Use of a polyanionic polysaccharide solution for the prevention of abscess formation |
| 10/25/2001 | WO2001079480A1 Albumin fusion proteins |
| 10/25/2001 | WO2001079444A2 Albumin fusion proteins |
| 10/25/2001 | WO2001079443A2 Albumin fusion proteins |
| 10/25/2001 | WO2001079442A2 Albumin fusion proteins |
| 10/25/2001 | WO2001079271A1 Albumin fusion proteins |
| 10/25/2001 | WO2001079258A1 Albumin fusion proteins |
| 10/25/2001 | WO2001025238A3 Heterocyclic compounds useful as inhibitors of tyrosine kinases |
| 10/25/2001 | CA2747325A1 Albumin fusion proteins |
| 10/25/2001 | CA2405709A1 Albumin fusion proteins |
| 10/25/2001 | CA2405701A1 Albumin fusion proteins |
| 10/25/2001 | CA2405563A1 Albumin fusion proteins |
| 10/25/2001 | CA2405557A1 Albumin fusion proteins |
| 10/25/2001 | CA2405550A1 Albumin fusion proteins |
| 10/25/2001 | CA2405525A1 Albumin fusion proteins |
| 10/24/2001 | EP1147119A1 2,3-o-isoproylidene derivatives of monosaccharides as cell adhesion inhibitors |
| 10/18/2001 | WO2001077137A1 Albumin fusion proteins |
| 10/18/2001 | WO2001077085A1 Quinazoline compounds |
| 10/18/2001 | WO2001038316A3 Sulfonyl oxazole amines and their use as 5-ht6 receptor ligands |
| 10/18/2001 | CA2405912A1 Albumin fusion proteins |
| 10/18/2001 | CA2403365A1 Quinazoline compounds |
| 10/17/2001 | EP1144441A2 Disintegrin homologs |
| 10/17/2001 | EP1144396A2 Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents |
| 10/17/2001 | EP1144381A2 Substituted benzo[de]isoquinoline-1,3-diones |
| 10/17/2001 | EP1143964A1 2-adamantanemethanamine compounds for treating abnormalities in glutamatergic transmission |
| 10/17/2001 | CN1317952A Improved method for targeted topial treatment of disease |
| 10/10/2001 | EP1141364A1 Use of the cell's own transport system for transferring nucleic acids across the nuclear membrane |
| 10/10/2001 | EP1141015A1 Insulin-like growth factor (igf) i mutant variants |
| 10/10/2001 | EP1140901A2 Substituted (aminoiminomethyl or aminomethyl)benzoheteroaryl compounds as factor xa inhibitors |
| 10/10/2001 | EP1140194A2 Use of cyclooxygenase-2 inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combined treatment of neoplasia |
| 10/10/2001 | EP1140193A2 Use of an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| 10/10/2001 | EP1140192A2 Use of a cyclooxygenase-2 inhibitor and one or more antineoplastic agents for combination therapy in neoplasia |
| 10/10/2001 | EP1140183A1 Use of a matrix metalloproteinase inhibitor and an integrin antagonist in the treatment of neoplasia |
| 10/10/2001 | EP1140182A2 Use of a matrix metalloproteinase inhibitor together with an antineoplastic agent, optionally also together with radiation, in the treatment of neoplasia |
| 10/10/2001 | EP1140179A2 Use of a cyclooxygenase 2 inhibitor and an integrin antagonist as a combination therapy in the treatment of neoplasia |
| 10/10/2001 | EP1140178A2 Use of a matrix metallaproteinase inhibitor and radiation as a combined treatment of neoplasia |
| 10/10/2001 | EP1140177A2 Use of an integrin antagonist and radiation in the treatment of neoplasia |
| 10/10/2001 | EP1140175A2 Antibodies to truncated vegf-d and uses thereof |
| 10/10/2001 | CN1316901A The use of fumaric acid derivatives in transplant medicine |
| 10/10/2001 | CN1072644C 4-fluoroalkyl substituted phenacyl guanidine, its prpearing method, application as medicine or diagnosis agent and medicine containing such compound |
| 10/04/2001 | WO2001072292A2 Vitamin d compounds used to stabilize kidney transplants |
| 10/04/2001 | EP1137405A1 Active ingredient matrix in the form of a biologically resorbable porous non-woven made of collagen fibrils, method for the production and use thereof |
| 09/27/2001 | WO2001071004A2 Proteases |
| 09/27/2001 | WO2001070734A2 Beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha |
| 09/27/2001 | WO2001070246A1 Use of lactic acid bacterium for the treatment of peritonitis |
| 09/27/2001 | WO2001070229A1 Thrombin inhibitors |
| 09/27/2001 | CA2403558A1 Thrombin inhibitors |
| 09/27/2001 | CA2403491A1 Use of lactic acid bacterium for the prevention of peritonitis |
| 09/27/2001 | CA2402763A1 Proteases |
| 09/27/2001 | CA2400168A1 Beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha |
| 09/20/2001 | WO2001068860A1 Antibodies to human cd154 |
| 09/20/2001 | WO2001068591A1 Carboxylic acid derivatives as ip antagonists |
| 09/20/2001 | WO2001068079A2 Viscoelastics for use in middle ear surgery |
| 09/20/2001 | WO2001068033A2 Il-8 receptor antagonists |
| 09/20/2001 | CA2400106A1 Antibodies to human cd154 |
| 09/13/2001 | WO2001066550A2 Compounds for pdt |
| 09/13/2001 | WO2001066140A1 Use of tgf-beta antagonists to treat or to prevent loss of renal function |
| 09/13/2001 | WO2001066107A2 Treatment of diseases associated with cytokine production with inhibitors of the tec family of protein tyrosine kinases |
| 09/13/2001 | WO2001030759A3 Sodium-hydrogen exchanger type 1 inhibitor crystals |
| 09/13/2001 | CA2402433A1 Compounds for pdt |
| 09/13/2001 | CA2401323A1 Treatment of diseases associated with cytokine production with inhibitors of the tec family of protein tyrosine kinases |
| 09/13/2001 | CA2400628A1 Use of tgf-beta antagonists to treat or to prevent loss of renal function |
| 09/12/2001 | EP1131085A2 Use of parvovirus capsid particles in the inhibition of cell proliferation and migration |
| 09/11/2001 | US6288098 Administering n-(4-trifluoromethyl)-5-methylisoxazole-4-carboxanilide and n-(4-trifluoromethylphenyl)-2-cyano-3-hydroxycrotonamide |
| 09/07/2001 | WO2001064650A2 Synthesis of epothilones, intermediates thereto and analogues thereof |
| 09/07/2001 | WO2001064214A2 Compositions and methods for the treatment of inflammatory diseases using topoisomerase inhibitors |
| 09/07/2001 | WO2000075107A3 Bradykinin receptor antagonists |